New RNA drug takes on tough liver tumors
NCT ID NCT07580261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new RNA-based drug called YMN-A02 in 10 people with advanced liver cancer that has stopped responding to standard treatments. The drug is designed to boost the immune system by blocking two cancer defenses at once. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YMN-A02 (a bifunctional RNA agent that produces a CTLA-4 antibody and TGF-β blocker)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced liver cancer that doesn't respond to current therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 10 people, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
West China Hospital
Chengdu, Sichuan, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?